Craig Slingluff
Directeur/Membre du Conseil chez Cancer Research Institute
Profil
Craig Slingluff is a member of the Scientific Advisory Council at Cancer Research Institute and a member of the Scientific Advisory Board at Immatics Biotechnologies GmbH.
Postes actifs de Craig Slingluff
| Sociétés | Poste | Début |
|---|---|---|
Cancer Research Institute
 Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Directeur/Membre du Conseil | - |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Cancer Research Institute
Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Health Services |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
